ResMed Inc. (RMD) Down 4.7% — Time to Get Out While Ahead?
ResMed Inc. (RMD) endured a punishing session today, shedding $10.52 to close at $212.72 on the NYSE. The damage extends well beyond a single bad day — the stock now sits roughly 27.6% below its 52-week high of $293.81, reached on August 22, 2025, a gap that underscores how much ground shareholders have lost over the past year and how far the recovery would need to travel to reclaim those levels.
Trading volume came in at approximately 921,573 shares, meaningfully below the 90-day average of around 1.4 million. The lighter turnover is a notable detail given the severity of the decline — selling pressure was concentrated rather than broadly panic-driven. Still, a 4.71% drop on subdued volume is not reassuring; it suggests the sellers who showed up had conviction, even if the broader crowd stayed on the sidelines.
Why ResMed Inc. Price is Moving Lower
The primary catalyst behind today's selloff is a combination of an earnings miss on the revenue line and a conservative fiscal 2027 outlook that landed poorly with investors. ResMed reported fiscal Q4 2026 revenue of $1.46 billion, falling short of Wall Street's roughly $1.47 billion estimate. While earnings per share technically beat expectations, the market made clear that the top-line miss and the muted forward guidance mattered more. Management flagged approximately $75 million of revenue headwind tied to the Astral ventilator field safety action — a specific, quantified drag that will weigh on results going into fiscal 2027. Additionally, the planned divestiture of MatrixCare and the recently completed $340 million acquisition of Noctrix Health were both cited as factors expected to dilute EPS next year, giving investors little near-term cushion to offset the revenue shortfall.
Analyst sentiment added to the pressure. Morgan Stanley downgraded ResMed from Overweight to Equalweight and cut its price target sharply from $286 to $230 on August 7, 2026. The firm cited limited near-term margin expansion, conservative earnings assumptions, and the possibility of renewed competition from Philips in the U.S. APAP market — a competitive threat that had been somewhat in the background but is back on investors' radar. Morgan Stanley also pointed to longer-term demand risk from GLP-1 weight-loss drugs, a concern that has periodically rattled sleep therapy stocks and appears to be gaining renewed traction. A downgrade of that magnitude, from one of the more influential voices on the Street, can independently move a stock — and on a day already burdened by guidance disappointment, the combination was particularly damaging.
Adding a secondary layer of unease, Director Peter C. Farrell sold 8,000 shares at $225 on August 5 in a pre-arranged Rule 10b5-1 plan. Planned insider sales carry less signal than open-market transactions, but the timing — two days before the earnings release and the subsequent selloff — drew attention and likely contributed to the nervous tone around the stock heading into the session.
What is the ResMed Inc. Rating - Should I Sell?
Weiss Ratings assigns RMD a C- rating. Current recommendation is Hold. That assessment reflects a company with genuinely strong underlying business metrics that are being offset by mounting near-term headwinds — a profile that warrants caution rather than outright exit, but also falls well short of inspiring confidence at this stage.
The fundamental scorecard carries real strengths. Revenue growth of 10.81% earns the Excellent Growth Index — a solid clip for a medical device and software company navigating a period of post-pandemic demand normalization in its core sleep therapy markets. A profit margin of 27.43% supports the Excellent Efficiency Index, which is a standout figure for a health care equipment business managing regulatory actions, integration costs from the Noctrix acquisition, and a pending divestiture simultaneously. ROE of 25.25% further supports the Excellent Efficiency Index — reflecting management's ability to generate strong returns on capital even as the business absorbs the MatrixCare restructuring. The Excellent Solvency Index rounds out the positives, suggesting the balance sheet can absorb the $340 million Noctrix outlay without threatening financial stability.
Where the C- rating reveals its honest assessment is in the performance-facing indices. The Weak Total Return Index is a candid reflection of what shareholders have actually experienced — a stock more than 27% off its 52-week high, now pressured further by guidance cuts and analyst downgrades. The Weak Volatility Index is equally relevant here: meaningful price swings have been a recurring feature of RMD over the past year, and today's 4.71% single-session drop adds to that pattern. For investors with lower risk tolerance, those two weak indices are not abstract concerns — they describe the actual cost of holding this position.
Within the Health Care sector, ResMed is on par with UnitedHealth Group Incorporated (UNH, C-) and Abbott Laboratories (ABT, C-), and a step below Intuitive Surgical, Inc. (ISRG, C), Stryker Corporation (SYK, C), and Medtronic plc (MDT, C). That relative positioning reinforces the Hold stance — ResMed is not the weakest name in its peer group, but it is not outperforming either, and the near-term fundamental headwinds give little reason to expect a quick reversal in that standing.
About ResMed Inc.
ResMed Inc. (RMD) is a Health Care company focused on developing and commercializing cloud-connected medical devices and software solutions for people living with sleep-disordered breathing, chronic obstructive pulmonary disease, and other respiratory conditions. The company's core product line centers on continuous positive airway pressure and automatic positive airway pressure devices — commonly known as CPAP and APAP — along with masks, accessories, and supporting respiratory care equipment distributed through health care providers and home medical equipment suppliers in more than 140 countries.
Beyond its hardware franchise, ResMed has invested substantially in digital health infrastructure, building an ecosystem of connected devices that transmit patient data through its cloud-based platform, AirView. This remote monitoring capability enables providers to manage patient compliance and therapy outcomes at scale — a differentiated capability that deepens customer relationships and creates recurring revenue streams tied to ongoing patient engagement. The company also serves the healthcare software market through its out-of-hospital software segment, which includes platforms designed to support home health agencies, hospice providers, and residential care operators, though the planned divestiture of MatrixCare signals a strategic narrowing back toward its core device and software-for-respiratory-care identity.
ResMed's competitive position rests on its installed base of connected devices, the depth of its clinical data assets, and a strong pipeline of next-generation products. Its relationships with large health systems, payors, and home care networks provide distribution advantages that are difficult for new entrants to replicate quickly. The company faces ongoing competitive pressure in its device categories and increasing scrutiny around longer-term demand dynamics tied to GLP-1 therapies, but its scale in sleep therapy, proprietary data platform, and global distribution network remain meaningful structural advantages in an industry where clinical evidence and provider trust carry significant weight.
Investor Outlook
ResMed Inc. (RMD) carries a Weiss Rating of C- (Hold), and investors face a genuinely mixed setup heading into fiscal 2027 — strong underlying margins and growth metrics running against revenue headwinds from the Astral ventilator safety action, EPS dilution from recent M&A, a Morgan Stanley downgrade, and unresolved longer-term questions around GLP-1 competition. The near-term watchpoints are clear: whether management can restore top-line momentum, how the Noctrix integration progresses, and whether the GLP-1 narrative intensifies or fades as clinical data accumulates. See full rankings of all C--rated Health Care stocks inside the Weiss Stock Screener.
--